West Expands Portfolio with New Ophthalmic Drug Delivery Packaging Solution

NovaPure® 0.5 mL plunger for ISO glass syringes now available

EXTON, Pa., April 29, 2026 -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today it has launched the NovaPure® 0.5 mL plunger for ISO glass syringes designed to meet the performance and quality requirements for ophthalmic drug applications. The plunger is West’s newest ready-to-use elastomer component within the NovaPure® portfolio, which includes the existing 1 mL and 1-3 mL plunger designs.

“The growing elderly population is driving an increase in age-related eye conditions, and demand for ophthalmic injectables is rising rapidly. This trend places greater pressure on delivery systems to overcome challenges such as silicone oil contamination, stringent particulate and endotoxin requirements, and the need for highly precise dosing,” said Stacey Vaughan, Vice President, Strategic Portfolio Management. “With the NovaPure® 0.5 mL plunger, West offers a patient-focused solution designed to help ensure drug stability, delivery precision, and reliable performance.”

The NovaPure® 0.5 mL plunger is designed to reduce the risk of free silicone oil, has exceptionally low particulate and endotoxin profiles, and highly consistent functional performance at microvolumes—key factors in supporting drug developers with ophthalmic applications. The solution optimizes break-loose and glide forces, reduces drug–package interactions, and supports compliance with global ophthalmic quality expectations, including Annex 1 requirements.

For more information visit West’s Ophthalmic delivery page here.

Forward-Looking Statements

Certain forward-looking statements are included in this press release. They use words such as “ensure,” “meet,” “supports,” “optimizes," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. Specifically, there is no certainty that West’s introduction of the NovaPure® 0.5 mL plunger for ISO glass syringes will achieve any particular result. These forward-looking statements involve a number of risks and uncertainties. Various factors could cause the actual results to differ materially from those expressed in, or underlying, these forward-looking statements, such as customers’ changing inventory requirements and manufacturing plans; customer decisions to move forward with new products and product categories; average profitability, or mix, of the products offered for sale; dependence on third party suppliers and partners; interruptions or weaknesses in the supply chain; increased raw material costs; fluctuations in currency exchange; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2024. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index. For more information, visit www.westpharma.com.